Modulation of regional brain activation in schizophrenic patients by pharmacological therapy with amisulpride, olanzapine or haloperidol. A study with functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI).

Trial Profile

Modulation of regional brain activation in schizophrenic patients by pharmacological therapy with amisulpride, olanzapine or haloperidol. A study with functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2008

At a glance

  • Drugs Amisulpride; Haloperidol; Olanzapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2008 Actual patient number (19) added as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Sep 2007 as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top